



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	327312	METAGENICS METAPURE ENTERIC
ARTG entry for	Medicine Listed	
Sponsor	Metagenics (Aust) Pty Ltd	
Postal Address	PO Box 675, VIRGINIA BC, QLD, 4014 Australia	
ARTG Start Date	11/12/2019	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . METAGENICS METAPURE ENTERIC

Product Type	Effective Date
Single Medicine Product	11/12/2019

Permitted Indications

- Helps maintain/support healthy eye development
- Maintain/support eye health
- Maintain/support general health and wellbeing
- Anti-inflammatory/relieve inflammation
- Helps in the maintenance of healthy blood lipids/blood fats
- Helps maintain/support healthy cholesterol
- Maintain/support cardiovascular system health
- Maintain/support heart health
- Maintain/support cognitive function/mental function
- Maintain/support nervous system health
- Maintain/support brain/central nervous system development
- Maintain/support nervous system function

Indication Requirements

- Product presentation must not imply or refer to lowering or raising blood cholesterol levels from outside of the normal healthy range
- Product presentation must not imply or refer to mental illnesses, disorders or conditions.
- Product presentation must not imply or refer to serious cardiovascular conditions.
- Product presentation must not imply or refer to vision correction, faults or serious eye disease e.g. macular degeneration.
- Label statement: If symptoms persist, talk to your health professional.
- Product presentation must not imply or refer to neurological conditions or developmental delays.



Australian Government
Department of Health
Therapeutic Goods Administration

Product presentation must not imply or refer to lowering blood lipids, blood fats and triglycerides.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule soft enteric

Route of Administration Oral

Visual Identification

Active Ingredients

concentrated fish Omega-3 triglycerides	1 g
Equivalent: eicosapentaenoic acid	500 mg
Equivalent: docosahexaenoic acid	200 mg

Other Ingredients (Excipients)

Carnauba Wax

d-alpha-tocopherol

Gelatin

glycerol

methacrylic acid copolymer

mono- and di- glycerides

polysorbate 80

propylene glycol

purified water

sodium lauryl sulfate

Soya Oil

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary